Market closedNon-fractionalADR
Compass Pathways/CMPS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Compass Pathways
Compass Pathways plc is a United Kingdom-based biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. The Company is engaged in the development of psilocybin treatment, in which its investigational COMP360 psilocybin is administered in conjunction with psychological support, COMP360 psilocybin treatment. COMP360 is its proprietary psilocybin formulation that includes its pharmaceutical-grade polymorphic crystalline psilocybin, optimized for stability and purity. The Company’s initial focus is on treatment-resistant depression (TRD), comprising patients who are inadequately served by the current treatment paradigm. It commenced its Phase III program evaluating its COMP360 psilocybin treatment in TRD. In addition, the Company has ongoing Phase II trials in PTSD and anorexia nervosa. It also provides support to research institutions conducting investigator-initiated studies with COMP360 psilocybin in areas of serious unmet need.
Ticker
CMPS
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology & Drugs
Headquarters
Altrincham, United Kingdom
Employees
186
Website
compasspathways.com
Compass Pathways Metrics
BasicAdvanced
$505M
Market cap
-
P/E ratio
-$2.37
EPS
2.33
Beta
-
Dividend rate
Price and volume
Market cap
$505M
Beta
2.33
52-week high
$12.75
52-week low
$5.01
Average daily volume
11
Financial strength
Current ratio
15.231
Long term debt to equity
11.225
Total debt to equity
11.225
Interest coverage (TTM)
-43.34%
Management effectiveness
Return on assets (TTM)
-53.68%
Return on equity (TTM)
-61.52%
Return on investment (TTM)
-57.32%
Valuation
Price to book
1.946
Price to tangible book (TTM)
1.947
Growth
Earnings per share change (TTM)
-6.63%
What the Analysts think about Compass Pathways
Analyst Ratings
Majority rating from 9 analysts.
Compass Pathways Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$35M
8.00%
Profit margin
0.00%
NaN%
Compass Pathways Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.62
-$0.67
-$0.53
-$0.55
-
Expected
-$0.69
-$0.43
-$0.33
-$0.49
-$0.53
Surprise
-10.66%
54.28%
60.61%
13.17%
-
Compass Pathways News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractionalADR
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Compass Pathways stock?
Compass Pathways (CMPS) has a market cap of $505M as of July 27, 2024.
What is the P/E ratio for Compass Pathways stock?
The price to earnings (P/E) ratio for Compass Pathways (CMPS) stock is 0 as of July 27, 2024.
Does Compass Pathways stock pay dividends?
No, Compass Pathways (CMPS) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Compass Pathways dividend payment date?
Compass Pathways (CMPS) stock does not pay dividends to its shareholders.
What is the beta indicator for Compass Pathways?
Compass Pathways (CMPS) has a beta rating of 2.33. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Compass Pathways stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.